154 related articles for article (PubMed ID: 31425178)
21. Four distinct ipsilateral vestibular schwannomas: A case of mosaic NF2-related schwannomatosis.
Tunkel AE; Youner ER; Barseghyan H; Fu Y; Bhattacharya S; Bornhorst M; Monfared AS
Am J Clin Pathol; 2024 Mar; ():. PubMed ID: 38527168
[TBL] [Abstract][Full Text] [Related]
22. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders.
Evans DGR; Salvador H; Chang VY; Erez A; Voss SD; Druker H; Scott HS; Tabori U
Clin Cancer Res; 2017 Jun; 23(12):e54-e61. PubMed ID: 28620005
[TBL] [Abstract][Full Text] [Related]
23. Multiple schwannomas: schwannomatosis or neurofibromatosis type 2?
Seppälä MT; Sainio MA; Haltia MJ; Kinnunen JJ; Setälä KH; Jääskeläinen JE
J Neurosurg; 1998 Jul; 89(1):36-41. PubMed ID: 9647170
[TBL] [Abstract][Full Text] [Related]
24. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
[TBL] [Abstract][Full Text] [Related]
25. Renal Cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2.
Sarkar S; Throckmorton W; Bingham R; Msaouel P; Genovese G; Slopis J; Rao P; Sadighi Z; Herzog CE
Curr Oncol; 2023 Mar; 30(3):3355-3365. PubMed ID: 36975468
[TBL] [Abstract][Full Text] [Related]
26. Constitutional LZTR1 mutation presenting with a unilateral vestibular schwannoma in a teenager.
Gripp KW; Baker L; Kandula V; Piatt J; Walter A; Chen Z; Messiaen L
Clin Genet; 2017 Nov; 92(5):540-543. PubMed ID: 28295212
[TBL] [Abstract][Full Text] [Related]
27. Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma.
Evans DG; Lye R; Neary W; Black G; Strachan T; Wallace A; Ramsden RT
J Neurol Neurosurg Psychiatry; 1999 Jun; 66(6):764-7. PubMed ID: 10329751
[TBL] [Abstract][Full Text] [Related]
28. Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing.
Evans DG; King AT; Bowers NL; Tobi S; Wallace AJ; Perry M; Anup R; Lloyd SKL; Rutherford SA; Hammerbeck-Ward C; Pathmanaban ON; Stapleton E; Freeman SR; Kellett M; Halliday D; Parry A; Gair JJ; Axon P; Laitt R; Thomas O; Afridi S; Ferner RE; Harkness EF; Smith MJ;
Genet Med; 2019 Jul; 21(7):1525-1533. PubMed ID: 30523344
[TBL] [Abstract][Full Text] [Related]
29. [Phenotype-genotype study in 154 French NF2 mutation carriers].
Demange L; De Moncuit C; Thomas G; Olschwang S
Rev Neurol (Paris); 2007 Nov; 163(11):1031-8. PubMed ID: 18033041
[TBL] [Abstract][Full Text] [Related]
30. Monitoring of optic nerve function in Neurofibromatosis 2 children with optic nerve sheath meningiomas using multifocal visual evoked potentials.
Jayanetti V; Klistorner AI; Graham SL; Dexter M; Flaherty MP; Jones K; Billson FA; Wilson M; North K; Grigg JR; Fraser CL
J Clin Neurosci; 2018 Apr; 50():262-267. PubMed ID: 29398196
[TBL] [Abstract][Full Text] [Related]
31. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
[TBL] [Abstract][Full Text] [Related]
32. Neurofibromatosis type 2.
Slattery WH
Otolaryngol Clin North Am; 2015 Jun; 48(3):443-60. PubMed ID: 26043141
[TBL] [Abstract][Full Text] [Related]
33. Neurofibromatosis type 2 (NF2): diagnosis and management.
Lloyd SK; Evans DG
Handb Clin Neurol; 2013; 115():957-67. PubMed ID: 23931824
[TBL] [Abstract][Full Text] [Related]
34. Cochlear implants in the management of hearing loss in Neurofibromatosis Type 2.
Harris F; Tysome JR; Donnelly N; Durie-Gair J; Crundwell G; Tam YC; Knight RD; Vanat ZH; Folland N; Axon P
Cochlear Implants Int; 2017 May; 18(3):171-179. PubMed ID: 28335700
[TBL] [Abstract][Full Text] [Related]
35. Revisiting the UK Genetic Severity Score for NF2: a proposal for the addition of a functional genetic component.
Catasús N; Garcia B; Galván-Femenía I; Plana A; Negro A; Rosas I; Ros A; Amilibia E; Becerra JL; Hostalot C; Rocaribas F; Bielsa I; Lazaro Garcia C; de Cid R; Serra E; Blanco I; Castellanos E;
J Med Genet; 2022 Jul; 59(7):678-686. PubMed ID: 34348961
[TBL] [Abstract][Full Text] [Related]
36. Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2.
Baser ME; Makariou EV; Parry DM
J Neurosurg; 2002 Feb; 96(2):217-22. PubMed ID: 11838793
[TBL] [Abstract][Full Text] [Related]
37. Progression of hearing loss in neurofibromatosis type 2 according to genetic severity.
Emmanouil B; Houston R; May A; Ramsden JD; Hanemann CO; Halliday D; Parry A; Mackeith S
Laryngoscope; 2019 Apr; 129(4):974-980. PubMed ID: 30456886
[TBL] [Abstract][Full Text] [Related]
38. Unilateral vestibular schwannoma in a patient with schwannomatosis in the absence of LZTR1 mutation.
Mehta GU; Feldman MJ; Wang H; Ding D; Chittiboina P
J Neurosurg; 2016 Dec; 125(6):1469-1471. PubMed ID: 26848914
[TBL] [Abstract][Full Text] [Related]
39. Multiple unilateral schwannomas: segmental neurofibromatosis type 2 or schwannomatosis?
Leverkus M; Kluwe L; Röll EM; Becker G; Bröcker EB; Mautner VF; Hamm H
Br J Dermatol; 2003 Apr; 148(4):804-9. PubMed ID: 12752143
[TBL] [Abstract][Full Text] [Related]
40. Early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype-phenotype correlation with targeted deep sequencing.
Teranishi Y; Miyawaki S; Nakatomi H; Ohara K; Hongo H; Dofuku S; Okano A; Takayanagi S; Ota T; Yoshimura J; Qu W; Mitsui J; Morishita S; Tsuji S; Saito N
Sci Rep; 2022 Jun; 12(1):9543. PubMed ID: 35681071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
